A Multicentre Randomised Placebo-Controlled Double-Blind Clinical Trial for Evaluation of Safety and Efficacy of Specific Immunotherapy With an Alum.-Adsorbed Allergoid Preparation of House Dust Mite (D. Pteronyssinus) in Patients With Allergic Bronchial Asthma, Rhinitis, Rhinoconjunctivitis.

Trial Profile

A Multicentre Randomised Placebo-Controlled Double-Blind Clinical Trial for Evaluation of Safety and Efficacy of Specific Immunotherapy With an Alum.-Adsorbed Allergoid Preparation of House Dust Mite (D. Pteronyssinus) in Patients With Allergic Bronchial Asthma, Rhinitis, Rhinoconjunctivitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jan 2015

At a glance

  • Drugs House dust mite allergy immunotherapy (Primary) ; Fluticasone propionate
  • Indications Allergic asthma; Asthma; Hypersensitivity; Rhinitis; Rhinoconjunctivitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Allergopharma
  • Most Recent Events

    • 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Jun 2012 Planned end date changed from 1 Apr 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.
    • 14 Oct 2011 Planned end date changed from 1 Feb 2010 to 1 Apr 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top